Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 125Neoplasm Metastasis 17Ovarian Neoplasms 12Endometrial Neoplasms 9Neoplasms 8Triple Negative Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 5Prostatic Neoplasms 5Hereditary Sensory and Autonomic Neuropathies 5Colorectal Neoplasms 5Advanced Breast Cancer 5Squamous Cell Carcinoma of Head and Neck 4Stomach Neoplasms 3Recurrence 3Neoplasms by Site 3Head and Neck Neoplasms 3Carcinoma, Lobular 3Breast Diseases 3Breast Cancer Metastatic 3Uterine Neoplasms 2Small Cell Lung Carcinoma 2Multiple Endocrine Neoplasia Type 1 2Melanoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Solid Tumors 2Urologic Neoplasms 1Urogenital Neoplasms 1

Interventions

capivasertib 2Fulvestrant 2ribociclib 1palbociclib 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Locally Advanced (Inoperable) or Metastatic Breast Cancer × Fulvestrant × 1 year × Clear all
NCT04862663 2026-05-27

CAPItello-292

AstraZeneca

Phase 3 Recruiting
895 enrolled
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT04305496 2026-04-30

CAPItello-291

AstraZeneca

Phase 3 Active not recruiting
818 enrolled 19 charts 2 FDA
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡